Supplementary Table I. Model 1A and 1B summary

Summary Model 1				
Model	**CC**	**R square**	**Adjusted R square**	**Standard error of estimate**
1A	0.67	0.45	0.46	52.1
1A*	0.96	0.95	0.87	17.0
1B	0.50	0.26	0.25	75.0
1B#	0.98	0.97	0.94	39.3

Predictors: (constant), body surface area (BSA). Dependent variable: blood dose/standardized blood dose (*adjusted dose parameters less than or equal to 10 kg; #adjusted dose parameters greater than 10 kg); CC — correlation coefficient; R square — regression coefficient

Supplementary Table IIA. Validating equation (weight less than or equal to 10 kg)

Weight [kg]	BSA [m^2]	BD [15 mL/ /kg]	BD equation [BSA m^2]	BD [20 mL/ /kg]
2.0	0.16	30.0	33.63	40.0
2.5	0.19	37.5	43.52	50.0
3.0	0.21	45.0	50.11	60.0
3.5	0.24	52.5	60.00	70.0
4.0	0.26	60.0	66.59	80.0
4.5	0.28	67.5	73.19	90.0
5.0	0.30	75.0	79.787	100.0
5.5	0.32	82.5	86.38	110.0
6.0	0.34	90.0	92.97	120.0
6.5	0.36	97.5	99.56	130.0
7.0	0.38	105.0	106.16	140.0
7.5	0.40	112.5	112.75	150.0
8.0	0.42	120.0	119.34	160.0
8.5	0.44	127.5	125.94	170.0
9.0	0.46	135.0	132.53	180.0
9.5	0.47	142.5	135.83	190.0
10.0	0.49	150.0	142.42	200.0
10.4	0.51	156.0	149.02	208.0

BD — blood dose

Supplementary Table IIB. Validating equation (weight greater than 10 kg)

Weight [kg]	BSA [m^2]	BD [15 mL/ /kg]	BD [20 mL/ /kg]	BD equation [BSA m^2]
11.00	0.53	165.0	220.0	139.749
12.00	0.56	180.0	240.0	156.648
13.00	0.59	195.0	260.0	173.547
14.00	0.62	210.0	280.0	190.446
15.00	0.65	225.0	300.0	207.345
16.00	0.68	240.0	320.0	224.244
17.00	0.71	255.0	340.0	241.143
18.00	0.74	270.0	360.0	258.042
20.00	0.79	300.0	400.0	286.207
21.00	0.82	315.0	420.0	303.106
22.00	0.85	330.0	440.0	320.005
23.00	0.87	345.0	460.0	331.271
24.00	0.90	360.0	480.0	348.17
25.00	0.92	375.0	500.0	359.436
32.00	0.95	480.0	640.0	376.335
33.00	1.10	495.0	660.0	460.83
34.00	1.10	510.0	680.0	460.83
36.00	1.20	540.0	720.0	517.16

BD — blood dose

Supplementary Table IIIA. Statistical parameters (equation validation ≤10 kg bw)

Weight up to 10 kg						
		Body weight [kg]	Body surface area [m^2]	BD [15 mL/kg]	BD [20 mL/kg]	Calculated blood dose [mL]
Mean		6.24	0.34	93.66	124.88	94.9
Median		6.25	0.35	93.75	125.00	96.2
Standard deviation		2.65	0.11	39.89	53.19	35.5
Minimum		2.0	0.16	30.00	40.00	33.6
Maximum		10.4	0.51	156.00	208.00	149.0
	25	3.87	0.25	58.12	77.50	64.9
	50	6.25	0.35	93.75	125.00	95.7
	75	8.62	0.44	129.37	172.50	127.5

Supplementary Table IIIB. Statistical parameters (equation validation >10 kg bw)

Weight greater than 10 kg						
		Body weight [kg]	BSA [m^2]	BD [15 ml/kg]	BD [20 mL/kg]	Calculated blood dose [mL]
Mean		21.4	0.81	321.6	428.8	297.4
Median		20.5	0.80	307.5	410.0	294.7
Standard deviation		7.9	0.19	118.8	158.4	110.0
Minimum		11.0	0.53	165.0	220.0	139.7
Maximum		50.0	1.2	540.0	720.0	517.2
	25	15.75	0.67	221.3	315.0	203.1
	50	22.50	0.86	337.5	450.0	322.8
	75	34.50	1.12	401.3	690.0	363.7

STROBE Statement — checklist of items that should be included in reports of cohort studies

	Item No.	Recommendation	Page No.
Title and abstract	1	(a) Indicate study's design with a commonly used term in title or abstract	2
		(b) Provide in abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain scientific background and rationale for investigation being reported	4
Objectives	3	State specific objectives, including any prespecified hypotheses	5
Methods			
Study design	4	Present key elements of study design early in paper	6 (Figure 1)
Setting	5	Describe setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6

→

STROBE Statement (cont.) — checklist of items that should be included in reports of cohort studies

	Item No.	Recommendation	Page No.
Participants	6	(a) Give eligibility criteria, and sources and methods of selection of participants. Describe methods of follow-up	6
		(b) For matched studies, give matching criteria and number of exposed and unexposed	
Bias	9	Describe any efforts to address potential sources of bias	
Study size	10	Explain how study size was arrived at	7
Quantitative variables	11	Explain how quantitative variables were handled in analyses. If applicable, describe which groupings were chosen and why	7–8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	7–9
		(b) Describe any methods used to examine subgroups and interactions	7–9
		(c) Explain how missing data were addressed	9
		(d) If applicable, explain how loss to follow-up was addressed	9
		(e) Describe any sensitivity analyses	NA
Participants	13	(a) Report numbers of individuals at each stage of study — e.g. numbers potentially eligible, examined for eligibility, confirmed eligible, included in study, completing follow-up, and analyzed	Figure 1
		(b) Give reasons for non-participation at each stage	NA
		(c) Consider use of a flow diagram	
Descriptive data	14	(a) Give characteristics of study participants (e.g. demographic, clinical, social) and information on exposures and potential confounders	9
		(b) Indicate number of participants with missing data for each variable of interest	<10% of total included data
		(c) Summarize follow-up time (e.g. average and total amount)	7
Outcome data	15	Report numbers of outcome events or summary measures over time	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g. 95% confidence interval). Make clear which confounders were adjusted for, and why they were included	9–11
		(b) Report category boundaries when continuous variables were categorized	9–11
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time-period (NA)	NA
Other analyses	17	Report other analyses done — e.g. analyses of subgroups and interactions, and sensitivity analyses	9–11
Discussion			
Key results	18	Summarize key results with reference to study objectives	11
Limitations	19	Discuss limitations of study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	13
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	13
Generalizability	21	Discuss generalizability (external validity) of study results	11–13
Other information			
Funding	22	Give source of funding and role of funders for present study and, if applicable, for original study on which present article is based	Title page